广发医疗保健股票A（004851）成立日期2017年8月10日，最新规模51.85亿。今年以来收益10.16%，同 类排名3520/4195；近一年收益8.77%，同类排名3478/4179；成立以来收益78.07%。 广发医疗保健股票A（004851）基金经理为吴兴武。 12月30日，吉贝尔跌1.01%，截至发稿，报29.27元/股，成交1353.80万元，换手率0.23%，总市值58.37 亿元。 资料显示，江苏吉贝尔药业股份有限公司位于江苏省镇江市高新技术产业开发园区，成立日期2001年11 月13日，上市日期2020年5月18日，公司主营业务涉及专业从事药品研发、生产、销售。主营业务收入 构成为：利可君片72.72%，尼群洛尔片14.20%，玉屏风胶囊4.88%，其他4.53%，醋氯芬酸肠溶片 3.67%。 从吉贝尔十大流通股东角度 数据显示，广发基金旗下1只基金位居吉贝尔十大流通股东。广发医疗保健股票A（004851）三季度新 进十大流通股东，持有股数95.9万股，占流通股的比例为0.48%。根据测算，今日浮亏损失约28.77万 元。 责任编辑：小浪快报 截至发稿，吴兴武累计任职时间10年325天， ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ● 本次结项的首次公开发行股票募集资金投资项目（简称"首发募投项目"或"募投项目"）名称：研发中 心（新址）建设项目 一、募集资金基本情况 ■ 根据中国证券监督管理委员会（以下简称"中国证监会"）2020年4月7日作出的《关于同意江苏吉贝尔药 业股份有限公司首次公开发行股票注册的批复》（证监许可〔2020〕614号），同意江苏吉贝尔药业股 份有限公司（以下简称"公司"）首次公开发行人民币普通股（A股）4,673.54万股，每股面值1.00元，每 股发行价格为23.69元。本次公开发行募集资金总额为人民币1,107,161,626.00元，扣除各项发行费用人 民币86,273,164.81元（不含税），募集资金净额为人民币1,020,888,461.19元。 信永中和会计师事务所（特殊普通合伙）对公司本次发行新股的资金到位情况进行了审验，并于2020年 5月12日出具了《验资报告》（XYZH/2020SHA20316号）。 公司根据规定对募集资金采取了专户存储管 ...

Core Viewpoint - The stock of Jibeier has experienced a decline recently despite a year-to-date increase, indicating potential volatility in its market performance [2]. Group 1: Stock Performance - As of November 19, Jibeier's stock price decreased by 2.00%, trading at 29.33 CNY per share with a total market capitalization of 5.849 billion CNY [1]. - Year-to-date, Jibeier's stock has risen by 34.05%, but it has seen a decline of 5.99% over the last five trading days, 8.00% over the last 20 days, and 21.28% over the last 60 days [2]. Group 2: Company Overview - Jibeier Pharmaceutical Co., Ltd. was established on November 13, 2001, and went public on May 18, 2020. The company specializes in the research, production, and sales of pharmaceuticals [2]. - The main revenue sources for Jibeier include Likujun tablets (72.72%), Nigulol tablets (14.20%), Yipingfeng capsules (4.88%), and others [2]. Group 3: Financial Performance - For the period from January to September 2025, Jibeier reported a revenue of 704 million CNY, reflecting a year-on-year growth of 9.52%, and a net profit attributable to shareholders of 197 million CNY, which is a 12.80% increase year-on-year [2]. - Since its A-share listing, Jibeier has distributed a total of 476 million CNY in dividends, with 252 million CNY distributed over the past three years [3]. Group 4: Shareholder Information - As of September 30, 2025, Jibeier had 7,742 shareholders, an increase of 28.97% from the previous period, with an average of 25,759 circulating shares per shareholder, a decrease of 22.46% [2]. - Notable new institutional shareholders include Caitong Advantage Industry Rotation Mixed Fund and GF Healthcare Stock A, holding 1.2392 million shares and 959,000 shares respectively [3].

Core Viewpoint - The company, Jibeier (688566), is focusing on expanding its market presence and product sales, particularly in underdeveloped regions, while also advancing its new drug development efforts, including an antidepressant and an oncology drug. Sales Strategy and Market Development - The company acknowledges significant sales disparities across regions and is implementing strategies to enhance sales in underperforming areas, aiming for regions like South and Central China to reach 80% of East China's sales levels [2] - The company has established a dedicated division and expert network to promote its hypertension drug, Niqunluo Tablets, which has shown strong sales growth, with over 7,000 hospitals covered as of September 2025, and an increase of 2,500 hospitals in the past year [2][11] Financial Performance - For the first three quarters of 2025, the company reported a main revenue of 704 million yuan, a year-on-year increase of 9.52%, and a net profit of 197 million yuan, up 12.8% [16] - In Q3 2025, the company achieved a single-quarter revenue of 249.5 million yuan, a 19.08% increase year-on-year, driven by sales growth in its core products [10][16] New Drug Development - The company is preparing to submit the application for its antidepressant drug JJH201501, which has completed Phase III clinical trials and demonstrated efficacy comparable to existing treatments [6][14] - The oncology drug JJH201601 is currently in Phase IIa trials, focusing on cholangiocarcinoma patients, with plans for further clinical trials in advanced head and neck cancers [9] Future Development Strategy - The company plans to leverage its product and technological advantages to expand the sales scale of key products like Likujun Tablets and Niqunluo Tablets, while also accelerating new drug development [7] - The company aims to enhance communication with the secondary market to improve its stock performance, despite recent underperformance [5]

Core Viewpoint - The stock of Jibeier has experienced a decline of 2.02% on November 10, with a current price of 31.01 CNY per share, despite a year-to-date increase of 41.73% [1] Financial Performance - For the period from January to September 2025, Jibeier achieved a revenue of 704 million CNY, representing a year-on-year growth of 9.52%, and a net profit attributable to shareholders of 197 million CNY, which is a 12.80% increase compared to the previous year [2] - Cumulative cash dividends since the A-share listing amount to 476 million CNY, with 252 million CNY distributed over the past three years [3] Shareholder Information - As of September 30, 2025, the number of shareholders for Jibeier is 7,742, an increase of 28.97% from the previous period, while the average circulating shares per person decreased by 22.46% to 25,759 shares [2] - The top ten circulating shareholders include new entrants such as Caitong Advantage Industry Rotation Mixed A and GF Healthcare Stock A, holding 1.2392 million shares and 959,000 shares respectively [3] Stock Market Activity - On November 10, Jibeier's trading volume reached 40.387 million CNY, with a turnover rate of 0.65% and a total market capitalization of 6.184 billion CNY [1] - The stock has seen a decline of 9.17% over the last five trading days, 6.60% over the last twenty days, and 1.30% over the last sixty days [1] Business Overview - Jibeier, established on November 13, 2001, and listed on May 18, 2020, is primarily engaged in the research, production, and sales of pharmaceuticals [1] - The main revenue sources include Likujun tablets (72.72%), Niqurol tablets (14.20%), Yupingfeng capsules (4.88%), and other products [1]

Core Viewpoint - The company has successfully completed Phase III clinical trials for its new antidepressant drug JJH201501, showing significant efficacy compared to placebo and comparable to a standard treatment, with good safety and tolerability [1] Group 1: Clinical Trials and Drug Development - JJH201501 has demonstrated significant efficacy in both 10mg and 15mg dosage groups compared to placebo, and is on par with the 20mg group of hydrobromide vortioxetine [1] - The company is preparing to submit a new drug application for JJH201501 [1] - The anticancer drug JJH201601 is currently undergoing a Phase IIa clinical trial for cholangiocarcinoma, with 21 patients enrolled, and results are expected in the first half of 2026 [1] - Plans are in place to expand JJH201601's application to head and neck squamous cell carcinoma combination therapy [1] Group 2: Financial Performance - For the first three quarters of 2025, the company achieved sales revenue of 704.43 million yuan, representing a year-on-year growth of 9.52% [1] - Revenue from Niquilol tablets reached 135.29 million yuan, showing a significant year-on-year increase of 47.09% [1] - Research and development expenses totaled 52.33 million yuan, with the majority allocated to ongoing projects like JJH201601, while capitalized costs were focused on JJH201501 [1] Group 3: Market Strategy - The company is strengthening its OTC channel layout, indicating that the outpatient market will become an important component of future growth [1]

Group 1: Company Performance - Xinbao Co., Ltd. reported a total revenue of 12.284 billion yuan for the first three quarters of 2025, a year-on-year decrease of 3.20%, while total profit increased by 1.84% and net profit attributable to shareholders rose by 7.13% [1] - Chaohongji achieved revenue growth and improved profitability through product innovation and operational enhancements, with a sales net profit margin of 7.8% [2] - Luwei Optoelectronics generated revenue of 827 million yuan, a year-on-year increase of 37.25%, and net profit of 172 million yuan, up 41.88% [3] - Huayi Long completed the development of its second-generation sequencing prototype and is advancing its product matrix and technology integration with AI platforms [4] - Jibeier's revenue for the first three quarters of 2025 reached 704 million yuan, with a significant year-on-year growth of 47.09% [5] - Xiangyu Medical is focusing on brain-computer interface technology, with plans to cover over 1,000 hospitals by next year [6] - Xinmai Medical reported a revenue of 300 million yuan for Q3 2025, with a net profit of 114 million yuan, showing a 60% year-on-year increase after excluding government subsidies [7] - Zoomlion has a supercomputing center with a GPU computing power of 59P, supporting extensive server and cloud capabilities [8] Group 2: Market Trends and Strategies - Xinbao's export orders are weak due to U.S. tariffs and global economic conditions, with a focus on Europe and North America for sales [1] - Chaohongji is expanding its market presence in Southeast Asia, having opened seven new stores [2] - Luwei Optoelectronics is a leader in advanced packaging and has achieved mass production at 180nm technology [3] - Jibeier is enhancing its OTC team to expand retail and e-commerce channels [5] - Xiangyu Medical is transitioning from passive to active rehabilitation technologies, focusing on non-invasive brain-computer interfaces [6] - Xinmai Medical's international business is growing rapidly, with overseas revenue increasing by over 65% [7] - Zoomlion's long-term strategic partnerships in high-end equipment manufacturing position it well for future project involvement [8] Group 3: Financial Metrics - Huayi Long's gross profit margin improved due to new product results, while its revenue for the first three quarters was 1.044 billion yuan, down 1.36% year-on-year [4] - Jibeier's R&D investment for the first three quarters was 52.33 million yuan, with expectations for stable overall spending next year [5] - Xiangyu Medical's short-term profits are under pressure, but long-term improvements are anticipated due to significant R&D investments [6] - Xinmai Medical's gross margin is expected to recover to over 70% for the year [7]

Group 1 - The core point of the news is that Jibeier's stock price increased by 5.07% to 34.62 CNY per share, with a trading volume of 213 million CNY and a turnover rate of 3.22%, resulting in a total market capitalization of 6.904 billion CNY [1] - Jibeier Pharmaceutical Co., Ltd. is located in the High-tech Industrial Development Zone of Zhenjiang, Jiangsu Province, established on November 13, 2001, and listed on May 18, 2020. The company specializes in drug research, production, and sales [1] - The main revenue composition of Jibeier includes: Likujun tablets 72.72%, Niqunlol tablets 14.20%, Yupingfeng capsules 4.88%, others 4.53%, and Acetylsalicylic Acid Enteric-coated Tablets 3.67% [1] Group 2 - From the perspective of the top ten holdings of funds, data shows that one fund under Guotai Fund has a significant position in Jibeier. Guotai Ju Li Value Regular Open Flexible Allocation Mixed Fund (005746) held 70,000 shares in the third quarter, accounting for 1.18% of the fund's net value, ranking as the fifth-largest holding [2] - The Guotai Ju Li Value Regular Open Flexible Allocation Mixed Fund (005746) was established on March 27, 2018, with a latest scale of 212 million CNY. Year-to-date return is 5.51%, ranking 6703 out of 8235 in its category; the one-year return is 6.2%, ranking 6652 out of 8105; and since inception, the return is 47.03% [2] Group 3 - The fund managers of Guotai Ju Li Value Regular Open Flexible Allocation Mixed Fund (005746) are Cheng Zhou and Cheng Yao. As of the report, Cheng Zhou has a cumulative tenure of 17 years and 216 days, with a total fund asset size of 7.788 billion CNY, achieving the best fund return of 386.87% and the worst return of -37% during his tenure [3] - Cheng Yao has a cumulative tenure of 4 years and 116 days, with a total fund asset size of 1.503 billion CNY, achieving the best fund return of 15.83% and the worst return of 5.11% during her tenure [3]

Group 1 - The core viewpoint of the news is that Jibeier's stock has shown significant fluctuations, with a year-to-date increase of 55.07% but a recent decline over the past five and twenty trading days [1] - As of October 16, Jibeier's stock price was 33.93 CNY per share, with a market capitalization of 6.767 billion CNY [1] - The company has experienced a net outflow of main funds amounting to 2.3898 million CNY, while large orders showed a mixed trend with buying at 5.0187 million CNY and selling at 8.2008 million CNY [1] Group 2 - For the first half of 2025, Jibeier reported a revenue of 455 million CNY, reflecting a year-on-year growth of 4.90%, and a net profit attributable to shareholders of 149 million CNY, which is a 22.38% increase compared to the previous year [2] - The company has distributed a total of 476 million CNY in dividends since its A-share listing, with 296 million CNY distributed over the last three years [3] Group 3 - Jibeier's main business includes drug research, production, and sales, with the primary revenue sources being Likujun tablets (72.72%), Niquinlor tablets (14.20%), and Yupingfeng capsules (4.88%) [1] - The company is categorized under the pharmaceutical and biological industry, specifically in chemical pharmaceuticals and preparations, and is involved in innovative drugs and cancer treatment [1]

Core Viewpoint - The stock of Jibeier has shown significant fluctuations, with a year-to-date increase of 52.10%, but recent declines in the short term indicate potential volatility in investor sentiment [1][2]. Group 1: Stock Performance - On October 15, Jibeier's stock rose by 2.02%, reaching a price of 33.28 CNY per share, with a trading volume of 18.48 million CNY and a turnover rate of 0.28% [1]. - The total market capitalization of Jibeier is 6.637 billion CNY [1]. - Year-to-date, the stock has increased by 52.10%, but it has decreased by 6.75% over the last five trading days and 8.42% over the last twenty days [1]. Group 2: Financial Performance - For the first half of 2025, Jibeier reported a revenue of 455 million CNY, representing a year-on-year growth of 4.90%, and a net profit attributable to shareholders of 149 million CNY, which is a 22.38% increase compared to the previous year [2]. - Since its A-share listing, Jibeier has distributed a total of 476 million CNY in dividends, with 296 million CNY distributed over the last three years [3]. Group 3: Business Overview - Jibeier, established on November 13, 2001, and listed on May 18, 2020, is primarily engaged in the research, production, and sales of pharmaceuticals [1]. - The main revenue sources for Jibeier include Likujun tablets (72.72%), Niqurolol tablets (14.20%), Yupingfeng capsules (4.88%), and other products [1]. - Jibeier operates within the pharmaceutical and biological industry, specifically in chemical pharmaceuticals and formulations, and is involved in innovative drugs and cancer treatment [1].